Applied StemCell provides industry and academic researchers with the ability to leverage the power of induced pluripotent stem cells (iPSC) technology.
Headquartered in Milpitas, California. Applied StemCell Inc. (ASC) is a fast growing biotechnology company headquartered in Milpitas, California.
07/03/2025
This Independence Day, we’re celebrating more than just our independence and freedom as a U.S.-based company—we're celebrating your ability to operate freely when we use MAD7 in your cell line engineering project.
Find out what it means to operate freely when choosing MAD7 vs. CRISPR/Cas9 for product development by clicking here: https://bit.ly/3TUwrkJ
At Applied StemCell, we’re here to support your cell line engineering projects. We've been empowering the scientific community for over 17 years, and routinely use MAD7 for gene editing in iPSCs, HEK293s, CHO cells, and other mammalian cell lines.
05/16/2025
WEBINAR: Getting cell therapies to IND faster: the advantages of off-the-shelf GMP iPSCs with a DMF
In the rapidly evolving cell therapy regulatory landscape, getting your cell therapy candidate to IND can be challenging. The process of procuring suitable donor material, reprogramming the cells under GMP requirements, and characterizing the iPSCs burns time and money.
Join our COO, Tim Largen, in our upcoming webinar as he discusses how off-the-shelf iPSC technology covered by a DMF benefits cell therapy development and overcomes the associated regulatory challenges.
Speak with Mike Yurkovich, Ph.D., and Heather Lundie at Booth 329 and learn how our TARGATT™ large knock-in technology can help you target your mammalian cell line engineering goals. Efficiently knock in genes at the transcriptionally active H11 locus and consistently express proteins—even hard-to-express proteins like membrane proteins—with TARGATT™.
We fuel your research and discovery in other ways, too. Our biologically relevant solutions in iPSC generation and differentiation, gene editing, and animal services are engineered to shorten timelines and ensure you can leave the lab confidently at the end of the day. Let’s work together to unleash the full power of biology and get more cell therapies to the market. Get started now with our business development experts at ISCT 2025 New Orleans. 🤝
04/18/2025
See you in Chicago 🥳
We are an Official Vendor at the AACR® Annual Meeting 2025! Meet with our business development team at Booth 4849 to unleash the full power of biology.
Find out how our gene-editing, iPSC, and animal services can empower your research and discovery. And with our ActiCells™ GMP Human Induced Pluripotent Stem Cells (hiPSC) now covered by a DMF with the US FDA and our ActiCells™ RUO Hypoimmune hiPSCs available, we are ready to accelerate your cell therapy development.
Together, we can get treatments into the hands of patients faster than ever. Come speak to Heather and Mike and let’s find a way to best support your needs... and maybe even get your hands on one of our new notebooks 👀
This post is not affiliated with or endorsed by AACR.
04/15/2025
We are thrilled to announce that the U.S. Food and Drug Administration (FDA) has accepted our Type II Drug Master File (DMF) for our ActiCells™ GMP Human Induced Pluripotent Stem Cell (hiPSC) line.
This milestone underscores our company’s commitment to empowering scientists to accelerate their cell therapy development by providing high-quality, regulatory-compliant iPSC solutions.
Our CEO Ruby Tsai, Ph.D., is excited because “By providing a fully characterized, regulatory-ready iPSC platform, we empower researchers to accelerate development while reducing manufacturing and regulatory hurdles.”
These manufacturing and regulatory hurdles are time-consuming—many patients don’t have the time for hurdles. By reducing these hurdles, our ActiCells™ GMP hiPSC line brings us closer to a future where treatments are more accessible.
Read more about our submission and how our ActiCells™ GMP hiPSC line can power your discovery and development here: https://bit.ly/3Ep9EcO
04/08/2025
We’re thrilled to unveil our new booth design at our upcoming events this Spring. Meet with us to learn how we can support you in unleashing the full power of biology (or just come admire our booth).
Whether you’re working on basic research, conducting discovery studies, or interested in GMP manufacturing, we enable you to leverage the power of induced pluripotent stem cell (iPSC) technology and gene editing.
Meet with our business development experts at the following events to find out how we can support your needs:
📍April 25-30, 2025: Booth 4849 at the American Association for Cancer Research (AACR) Annual Meeting
📍May 7-10, 2025: Booth 329 at the International Society for Cell and Gene Therapy’s ISCT 2025
📍May 12-16, 2025: PEGS Boston Summit (Poster number to be announced)
To learn more about how we power autologous and allogeneic discovery and development, or to schedule a time to meet, contact us here: https://bit.ly/3R6Lkzd
04/03/2025
TARGATT™ large knock-in technology is fueling advances in gene therapy development 💥
To lower costs and timelines for AAV production, our partners at CHO Plus unleashed the full power of cell line engineering with our TARGATT™ large knock-in technology.
While CHO Plus has not yet put the TARGATT™ technology into their optimized HEK293 cell lines that increase viral titer up to 4x and % full capsids up to 2x, they already see much better production of capsids in the cell line with a payload gene stably integrated into the H11 locus using TARGATT™ technology.
Hear Larry Forman, Founder and CEO of CHO Plus, present his team’s promising findings in the video below.
Watch the full webinar on improving therapeutic protein and viral vector production here: https://bit.ly/4ldFJVu
03/25/2025
Check out our new poster to achieve inducible expression with TARGATT™ large knock-in technology ✨🎯
With TARGATT™, you can achieve site-specific, single copy knock-ins of 20+ kb of DNA at efficiencies approaching or exceeding 90% after selection. Walk through the poster with our Director of Marketing, Pia Abola, Ph.D. below to find out how we can help you target your knock-in goals and unleash the full power of biology.
If you weren’t able to meet with Heather at BPI West or you would like to learn more about TARGATT™, view the poster here: https://hubs.ly/Q03dltfH0
03/18/2025
Enabling you to unleash the full power of life-saving biology ❤️
What if there was a treatment for hypertrophic cardiomyopathy to decrease the prevalence of sudden cardiac death? Greer-Short et al. set out to tackle this disease with two challenges to overcome: restoring cardiac function and optimizing the regulatory elements in the vector to do so.
Greer-Short et al. investigated the genetic basis of hypertrophic cardiomyopathy to target and treat the loss-of-function mutations in Myosin Binding Protein C3 (MYBPC3). In doing so, they created a method to improve the efficiency of their regulatory elements while meeting the size constraints of the AAV vector. The results from this packaging method showed restoration of cardiac function in MYBPC3 Exon1-Exon2 knockout mice, with an improvement in cardiac phenotypes and life expectancy.
We are excited about the critical research efforts of Greer-Short et al., and we are proud to have engineered the MYBPC3 Exon1-Exon2 knock-out mice used in their study that helped power their success. Please join us in celebrating the researchers’ contribution to gene therapy development that aims to reduce the prevalence of sudden cardiac death.
At Applied StemCell, we offer custom mouse gene-editing services for disease model generation, enabling research and powering the advanced therapeutics of tomorrow. Let's work together to unleash the full power of life-saving biology.
Our Senior Business Development Manager, Heather Lundie, MBA, will be at the BioProcess International US West convention in San Diego next week. Chat with Heather at Poster 27 to see how we can use TARGATT™ to help you unleash the full power of biology.
See you soon in San Diego! 🎉
03/11/2025
Join us at our upcoming webinar 📣 🙌
We are excited to announce our next webinar, presented by Larry Forman, Founder and CEO of CHO Plus. Come learn about a novel cell engineering approach for significantly improving therapeutic protein and viral vector production. Register below and join us on March 25, 2025, at 10:00am PST.
Can’t make it? We’ve got you covered 🤝
Registering ensures you’ll receive access to the webinar recording.
Stop by our booth at the Biotech Community Event at SOVA to meet with Heather Lundie and Wesley Chen. Find out how we can support your research with our induced pluripotent stem cell technology and gene editing platforms. Our TARGATT™ knock-in technology can help you target your dreams of DNA insertions that are efficient, site-specific, and as large as 20 kb in a single reaction.
Be the first to know and let us send you an email when Applied StemCell, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Applied StemCell Inc. (ASC) is a fast growing biotechnology company headquartered in Milpitas, California. Our goal is to advance gene-editing and stem cell innovationfor biomedical research and the biotechnology industry. After years of research and development, ASC is proud to offer an optimized series of tools for basic research study, drug discovery, bio-processing, bio-production and preclinical applications.
We are currently focusing on three areas:
Cell line generation for bio-production and bioassays
Patient-relevant cell models for personalized medicine and
Physiologically predictive animal models of human diseases
We are striving to improve and expand our technologies and product lines to meet the increasing requirements of the biomedical community.
Establishing disease-specific isogenic models
Developing master cell lines for antibody/protein production
Generating iPSCs from patients containing the corrected mutations or inserted genes for pre-clinical applications
Generating animal models (mouse/rat models)
Using our TARGATT™ technology, a gene-of-interest can be specifically inserted at a well-characterized, transcriptionally active locus in the genome with guaranteed transgene expression.
This site-specific Knock-in technology has been first established in mouse models, and we have successfully applied it to human cell lines.
We are moving forward to various projects that will combine the CRISPR/Cas9 technology and TARGATT™ for highly specified transgene expression.
